CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 270 enrolled
Drug / intervention
ranibizumabdrug
Likely dose
ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01908816
NCT01908816Phase 3Completed
CompareCT.gov

An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.

Novartis Pharmaceuticals·interventional·Posted Jul 26, 2013·Updated Aug 12, 2019

In Brief

A Phase 3 clinical trial evaluating ranibizumab for Choroidal Neovascularization and 3 related conditions. Completed, enrolled 270 participants across 39 sites.

Detailed Summary

The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoroidal Neovascularization, Macular Edema, Glaucoma, Neovascular, Diabetic Retinopathy
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 26, 2013
Enrollment StartSep 26, 2013
Primary CompletionJan 8, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.9 years ago

Interventions

ranibizumabdrug

One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)